T Cell News and Research

Latest T Cell News and Research

ISCO's therapeutic program not affected by stem cell research federal fund ban

International Stem Cell Corporation announced today that the recent action of a federal district judge blocking federal funding of embryonic stem cell research is not expected to have negative effects on ISCO's therapeutic programs using its human parthenogenetic stem cells.

27 Aug 2010

Researchers recommend traumatic brain injury reclassification for additional funding

Traumatic brain injury, currently considered a singular event by the insurance industry and many health care providers, is instead the beginning of an ongoing process that impacts multiple organ systems and may cause or accelerate other diseases and disorders that can reduce life expectancy, according to research from the University of Texas Medical Branch at Galveston.

27 Aug 2010

H1N1 flu increases complication in children with sickle cell anemia: Study

Children with sickle cell disease are especially hard-hit by the H1N1 flu strain, causing more life-threatening complications than the seasonal flu, according to a study from Johns Hopkins Children's Center.

27 Aug 2010

Nationwide Children's Hospital designated as Wellstone Muscular Dystrophy Cooperative Research Center

A $7 million grant from the National Institutes of Health (NIH) will help researchers at Nationwide Children's Hospital translate new scientific findings and technological developments into novel treatments for the muscular dystrophies. The grant designates Nationwide Children's Hospital as a Paul D. Wellstone Muscular Dystrophy Cooperative Research Center, one of three national award recipients in 2010.

27 Aug 2010

Researchers identify molecule to slow down dysfunctional immune response in hemorrhagic shock

Researchers have isolated a molecule, small enough to be used as a drug, that can shut down a dysfunctional immune response that causes deadly hemorrhagic shock, results in delayed death of heart attack patients, promotes rejection of transplanted organs and destroys joints in patients with rheumatoid arthritis, according to a paper published in Molecular Immunology.

27 Aug 2010

ThermoGenesis files Certificate of Amendment for reverse stock split

ThermoGenesis Corp.,a leading supplier of innovative products and services that process and store adult stem cells, said it has filed a Certificate of Amendment to its Amended and Restated Certification of Incorporation to effect its previously announced one-for-four reverse stock split of its common stock.

27 Aug 2010

Bioheart reports promising result for congestive heart failure treatment with stem cell therapy

Bioheart, Inc., announces that the treatments and 3 month follow up with stem cell therapy on the first two congestive heart failure patients has been performed successfully at Hospital Angeles Tijuana through its Center of Excellence, Regenerative Medicine Institute of Tijuana, Mexico.

27 Aug 2010

Study on impact of harmful de novo gene mutations on autism, schizophrenia

An international study led by University of Montreal scientists suggests family history may not be a good predictor of the presence of mutations predisposing to autism or schizophrenia. The findings show how new or de novo gene mutations alterations of the cell's DNA play a role in these devastating conditions.

27 Aug 2010

NICE suggests bortezomib, thalidomide for multiple myeloma patients

The National Institute for Health and Clinical Excellence (NICE) has released draft guidance which recommends the drugs bortezomib and thalidomide as first-line therapies for some patients with multiple myeloma, a type of cancer that affects cells in the bone marrow.

27 Aug 2010

Lysozyme can protect anthrax contamination in processed foods: Study

An antibacterial enzyme found in human tears and other body fluids could be applied to certain foods for protection against intentional contamination with anthrax, scientists reported here today at the 240th National Meeting of the American Chemical Society (ACS).

27 Aug 2010

Xcellerex, SK Chemicals sign memorandum of understanding to expand vaccine business in Korea

Xcellerex, Inc. announced today that it has signed a memorandum of understanding with SK Chemicals, Co., Ltd., one of South Korea's largest industrial groups, for an alliance to develop and commercialize SK-developed vaccines with Xcellerex's FlexFactory biomanufacturing platform. The companies expect to define specific terms of the alliance in the coming months.

26 Aug 2010

Pathogens can delay entry into cells to ensure their survival, say researchers

Pathogens make themselves feel at home in the human body, invading cells and living off the plentiful amenities on offer. However, researchers at the Max Planck Institute for Infection Biology, Berlin, together with colleagues at Harvard University, reveal an opposite strategy used to ensure infection success. Pathogens can actually delay their entry into cells to ensure their survival.

26 Aug 2010

Research on myosin II protein can lead to novel treatment for memory disorders

Scientists from the Florida campus of The Scripps Research Institute have discovered a mechanism that plays a critical role in the formation of long-term memory. The findings shed substantial new light on aspects of how memory is formed, and could lead to novel treatments for memory disorders.

26 Aug 2010

Motor proteins play critical role in stabilization of long-term memories

Functioning much like gears in a machine, cellular motor proteins are critical to dynamic functions throughout the body, including muscle contraction, cell migration and cellular growth processes. Now, neuroscientists from UC Irvine and the Florida campus of The Scripps Research Institute report that motor proteins also play a critical role in the stabilization of long-term memories. The findings add an unexpected dimension to the story of how memories are encoded and suggest new targets for therapeutic interventions.

26 Aug 2010

Treating metastatic melanoma tumors with specific genetic signature shows promising results

Use of an experimental targeted drug to treat metastatic melanoma tumors with a specific genetic signature was successful in more than 80 percent of patients in a phase 1 clinical trial.

26 Aug 2010

Researchers develop magnetic nanoparticles for metallic implant drug delivery

If a drug can be guided to the right place in the body, the treatment is more effective and there are fewer side-effects. Researchers at Lund University in Sweden have now developed magnetic nanoparticles that can be directed to metallic implants such as artificial knee joints, hip joints and stents in the coronary arteries.

26 Aug 2010

PLX4032 therapy results in tumor shrinkage in metastatic melanoma patients

A multicenter study has concluded that treatment with a new targeted therapy called PLX4032 (also called RG7204) resulted in significant tumor shrinkage in 80 percent of patients with advanced melanoma.

26 Aug 2010

Biomoda's CyPath assay for lung cancer detection receives Canadian patent

Cancer diagnostics company Biomoda, Inc. has received a notice of allowance for a Canadian patent application for a method of using its proprietary porphyrin-based compound that binds to cancer cells and causes them to fluoresce under specific frequencies of light when viewed under a fluorescent microscope.

26 Aug 2010

Critical mechanistic link between mutant protein and disease pathogenesis in ALS uncovered

New research uncovers what may be a primary neuron-damaging insult that occurs in an inherited form of a devastating neurodegenerative disorder. The study, published by Cell Press in the August 26th issue of the journal Neuron, describes a critical mechanistic link between a mutant protein and disease pathogenesis in an animal model of amyotrophic lateral sclerosis (ALS).

26 Aug 2010

NIH suspends funding new embryonic stem cell research following court order

"The National Institutes of Health announced Tuesday that it has suspended funding new human embryonic stem cell research and that all federally funded experiments already underway will be cut off when they come up for renewal if a new court order is not overturned. The announcement -- which confirmed fears among proponents that the ruling would result in a comprehensive freeze in federal support for stem cell research -- came in response to a court order Monday barring the government from funding the research because it involves the destruction of embryos.

26 Aug 2010